Get the Stockscreener App
30.00
2.04%
0.60
Lakefront Biotherapeutics Nv Adr stock is traded at $30.00, with a volume of 161.86K.
It is up +2.04% in the last 24 hours and up +7.45% over the past month.
Lakefront Biotherapeutics NV a biopharmaceutical company committed to improving the lives of people with severe diseases. It focuses on delivering medicines with transformational impact for patients by accelerating life-changing science and innovation in areas of high unmet need. Its pipelines includes GLPG3667, GLPG5101, and GLPG5301.
See More
Previous Close:
$29.40
Open:
$29.74
24h Volume:
161.86K
Relative Volume:
0.50
Market Cap:
$1.96B
Revenue:
$1.21B
Net Income/Loss:
$570.23M
P/E Ratio:
3.4654
EPS:
8.6571
Net Cash Flow:
$-293.03M
1W Performance:
+1.66%
1M Performance:
+7.45%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$29.71
$30.34
1-Week Range:
$28.50
$29.95
52-Week Range:
$25.68
$32.41
Lakefront Biotherapeutics Nv Adr Stock (LKFT) Company Profile
Name
Lakefront Biotherapeutics Nv Adr
Sector
Industry
Phone
-
Address
-
Compare LKFT vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LKFT
Lakefront Biotherapeutics Nv Adr
|
30.00 | 1.96B | 1.21B | 570.23M | -293.03M | 8.6571 |
VRTX
Vertex Pharmaceuticals Inc
|
508.71 | 128.94B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
238.63 | 95.27B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
799.98 | 82.36B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
855.28 | 53.79B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.53 | 42.37B | 5.76B | 514.49M | 1.10B | 4.4813 |
Lakefront Biotherapeutics Nv Adr Stock (LKFT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-23-26 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Aug-21-26 | Initiated | TD Cowen | Buy |
| Jul-10-26 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-22-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Aug-05-25 | Downgrade | Deutsche Bank | Hold → Sell |
| Feb-14-25 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Nov-20-24 | Downgrade | Kepler | Hold → Reduce |
| Sep-09-24 | Initiated | Leerink Partners | Market Perform |
| Aug-02-24 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Mar-28-24 | Downgrade | BofA Securities | Neutral → Underperform |
| Mar-07-24 | Resumed | Morgan Stanley | Equal-Weight |
| Aug-24-23 | Downgrade | Citigroup | Buy → Neutral |
| May-05-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jan-23-23 | Upgrade | Jefferies | Underperform → Hold |
| Nov-07-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Sep-09-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-27-22 | Upgrade | Citigroup | Neutral → Buy |
| Aug-19-21 | Downgrade | Barclays | Overweight → Equal Weight |
| Aug-06-21 | Downgrade | Deutsche Bank | Buy → Hold |
| Apr-20-21 | Initiated | Deutsche Bank | Buy |
View All
Lakefront Biotherapeutics Nv Adr Stock (LKFT) Latest News
Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Sees Strong Trading VolumeShould You Buy? - MarketBeat
Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Stock Now Rated "Moderate Buy" by Sell-Side Analysts - MarketBeat
Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Shares Gap Up After Analyst Upgrade - MarketBeat
Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Upgraded to "Outperform" at Royal Bank Of Canada - MarketBeat
Press Releases about Lakefront BiotherapeuticsAmerican Depositary Shares (Nasdaq:LKFT) - FinancialContent
Lakefront Biotherapeutics Targets 2027 Registrational Trials for Gamgertamig - Yahoo Finance
Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Sees Unusually-High Trading VolumeHere's Why - MarketBeat
InMode Ltd. (INMD) Stock Price & News - Syfe
Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
VALN Stock Price, Quote & News - Syfe
TD Cowen upgrades Lakefront Biotherapeutics stock rating to buy By Investing.com - Investing.com UK
TD Cowen upgrades Lakefront Biotherapeutics stock rating to buy - Investing.com
Analysts Offer Insights on Healthcare Companies: Fortrea Holdings Inc. (FTRE), AgomAb Therapeutics NV ADR (AGMB) and Sana Biotechnology (SANA) - theglobeandmail.com
argenx SE (ARGX) Stock Price, News, Quote & History - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Dogwood Therapeutics (DWTX), Talphera (TLPH) and 4D Molecular Therapeutics (FDMT) - The Globe and Mail
Analysts Have Conflicting Sentiments on These Healthcare Companies: Lakefront Biotherapeutics (LKFT), Prime Medicine, Inc. (PRME) and Electrocore (ECOR) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Wave Life Sciences (WVE), BrightSpring Health Services, Inc. (BTSG) and AgomAb Therapeutics NV ADR (AGMB) - The Globe and Mail
argenx SE (ARGX) stock price, news, quote and history - Yahoo Finance UK
Lakefront Biotherapeutics director resigns for Sanofi role By Investing.com - Investing.com Nigeria
Lakefront Biotherapeutics director resigns for Sanofi role - Investing.com
Lakefront Biotherapeutics director resigns for Sanofi role By Investing.com - Investing.com Canada
Lakefront Biotherapeutics stock coverage resumed at Equalweight by Morgan Stanley - Investing.com Nigeria
Lakefront Biotherapeutics stock coverage resumed at Equalweight by Morgan Stanley - Investing.com South Africa
Lakefront Biotherapeutics stock coverage resumed at Equalweight by Morgan Stanley - Investing.com India
Lakefront Biotherapeutics stock coverage resumed at Equalweight by Morgan Stanley - Investing.com
Lakefront Biotherapeutics stock coverage resumed at Equalweight by Morgan Stanley - Investing.com Canada
LKFTLakefront Biotherapeutics NV ADR Latest SEC Filings - Finviz
LKFTLakefront Biotherapeutics NV ADR Volatility & Greeks - Finviz
GXEA Forecast — Price Target — Prediction for 2027 - TradingView
Form 13G Lakefront Biotherapeutics NV For: 23 June By Investing.com - Investing.com South Africa
Form 13G Lakefront Biotherapeutics NV For: 23 June By Investing.com - Investing.com Nigeria
Form 13G Lakefront Biotherapeutics NV For: 23 June By Investing.com - Investing.com Canada
Gilead and Lakefront complete Ouro Medicines acquisition - Investing.com
Lakefront Biotherapeutics Shares Drop as LKFT Gets Reevaluated - Bez Kabli
LKFT - Finviz
Lakefront Receives Transparency Notification from Bank of America - Yahoo Finance Australia
LKFT.AS Stock Price, Quote & Chart | LAKEFRONT BIOTHERAPEUTICS (AMS:LKFT) - ChartMill
Earnings call transcript: Galapagos NV sees 91% revenue drop in Q1 2026 - Investing.com
Earnings call transcript: Galapagos NV sees 91% revenue drop in Q1 2026 - Investing.com Australia
Earnings call transcript: Galapagos NV sees 91% revenue drop in Q1 2026 - Investing.com Nigeria
Earnings call transcript: Galapagos NV sees 91% revenue drop in Q1 2026 - Investing.com India
Earnings call transcript: Galapagos NV sees 91% revenue drop in Q1 2026 - Investing.com Canada
LKFT: Lakefront BiotherapeuticsSponsored ADRCash Flow Statements - Zacks Investment Research
Lakefront Biotherapeutics American Depositary Shares (LKFT) Stock Price, News & Analysis - MarketBeat
Lakefront Biotherapeutics American Depositary Shares (LKFT) Earnings Date and Reports 2026 - MarketBeat
Lakefront Biotherapeutics American Depositary Shares (LKFT) Short Interest & Short Float | Updated Oct 2026 - MarketBeat
Lakefront Biotherapeutics American Depositary Shares (LKFT) Stock Forecast and Price Target 2026 - MarketBeat
LKFT: Lakefront BiotherapeuticsSponsored ADRComparison to Industry - Zacks Investment Research
LKFT : Lakefront BiotherapeuticsSponsored Adr Key Company Details - Zacks Investment Research
LKFT: Lakefront BiotherapeuticsSponsored ADRInsider Transations - Zacks Investment Research
Lakefront Biotherapeutics Nv Adr Stock (LKFT) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):